Dietary habits, commensal microbiome, and nasopharyngeal carcinoma by Huang, Tingting
 
 
From Department of Medical Epidemiology and Biostatistics 
Karolinska Institutet, Stockholm, Sweden 
DIETARY HABITS, COMMENSAL MICROBIOME, 










All previously published papers were reproduced with permission from the publisher. 
Front cover illustration: 壹日创意 and Tingting Huang 
Published by Karolinska Institutet. 
Printed by Universitetsservice US-AB, 2020 




Dietary Habits, Commensal Microbiome, 
and Nasopharyngeal Carcinoma 
 
THESIS FOR DOCTORAL DEGREE (Ph.D.) 
By 
Tingting Huang 
December 17 th, 2020. 09:00 a.m. 




Professor Weimin Ye 
Karolinska Institutet 




Professor Eva Munck af Rosenschöld Wikland 
Karolinska Institutet 
Department of Clinical Science, Intervention  
and Technology (CLINTEC) 
Division of ENT diseases 
Karolinska University Hospital 
Medical Unit Head Neck, Lung and Skin  
Cancer 
 
Assistant Professor Zongli Zheng 
Karolinska Institutet 
Ming Wai Lau Centre for Reparative  
Medicine 
 
Dr. Justine W. Debelius 
Karolinska Institutet 
Department of Microbiology, Tumor, and  
Cell Biology 
Centre for Translational Microbiome Research 
 
Opponent: 
Professor Maria Li Lung 
The University of Hong Kong 
LKS Faculty of Medicine 
Department of Clinical Oncology 
 
Examination Board: 
Docent Johan Dicksved 
Swedish University of Agricultural Sciences 
Department of Animal Nutrition and Management 
 
Professor Per Hall 
Karolinska Institutet 
Department of Medical Epidemiology and 
Biostatistics 
 
Professor Agneta Åkesson 
Karolinska Institutet 
Institute of Environmental Medicine 























To my parents for always believing in me 
致我最爱的爸爸妈妈 ❤ 
 











Nasopharyngeal carcinoma (NPC) is a malignant disease characterized by unique geographic 
distribution endemic to southern China, Southeast Asia, and the Middle East/North Africa. It 
has been widely accepted that the interaction of Epstein-Barr Virus infection, environmental 
and lifestyle factors, and genetic susceptibility, contributes to NPC carcinogenesis. In the past 
two decades, extensive application of intensity-modulated radiotherapy and widespread 
introduction of chemotherapy have significantly contributed to a desirable prognosis: better 
survival with fewer toxicities. However, there are still numerous knowledge gaps and unsolved 
questions about NPC risk and prognosis. In this thesis, we investigated whether dietary habits 
(Study I), and oral commensal microbiome (Study II) were associated with NPC risk, using a 
population-based case-control study in endemic southern China. We also conducted a 
longitudinal hospital-based NPC cohort study (Study III) to deliver proof-of-concept data on 
the commensal microbiome patterns in patients’ nasopharynx during radiotherapy and their 
role in NPC prognosis. 
In Study I/Paper I, we analyzed a total of 4398 study participants (2174 NPC cases and 2224 
controls) with data about adolescent diet and 4832 participants (2387 NPC cases and 2445 
controls) with data about adulthood diet. We demonstrated a strong positive association 
between higher consumption of the “animal-foods-based diet” and NPC risk and a strong 
negative association with higher intake of the “plant-based diet”. Following mutual adjustment 
for adolescence and adulthood dietary patterns, risk estimates for the former were attenuated 
and no longer statistically significant, whereas associations with adulthood dietary patterns 
remained virtually unchanged.  
In Study II/Paper II, we explored the relationship between NPC status and the oral microbiome 
using 16S rRNA sequencing in a study of 994 participants (499 NPC cases, 494 controls). We 
observed a significant reduction in community richness in NPC cases compared to that in 
controls. We also identified a pair of Granulicatella adiacens amplicon sequence variants 
(ASVs; Gran-7770 and Gran-5a37), which were strongly associated with NPC status and 
differed by a single nucleotide. We further revealed that Gran-7770 and Gran-5a37 each 
formed co-occurring nodes with a dozen ASVs, which were exclusive. These results suggest 
differences in the oral microbiomes between NPC patients and controls, which may be 
associated with both a loss of microbial diversity and niche specialization among closely 
related microorganisms. 
In Study III/Paper III, we analyzed 445 nasopharyngeal samples longitudinally collected from 
39 NPC patients during radiotherapy-based treatment. We addressed stable, temporal changes 
in the nasopharyngeal microbial community structure among NPC patients during treatment. 
These changes were associated with patients’ short-term clinical outcomes measured three 
months after the completion of radiotherapy. We also identified 23 out of 73 abundant ASVs 
that showed statistically significant changes in the ratio of abundance between early and late 
 
 
responders throughout treatment. These results provided evidence of an association between 
nasopharyngeal commensal microbiome and NPC patients’ short-term clinical outcome. 
By studying a range of topics, this thesis provides more insights into NPC in terms of risk and 
prognosis: plant-based and animal-foods-based diets are differentially associated with NPC 
risk in endemic southern China, suggesting a possibility of primary prevention of NPC through 
dietary intervention; oral microbiome is associated with NPC risk; the niche specialization 
among closely related commensals associated with NPC status calls for future culture-based 
investigations; moreover, stable, temporal changes of the nasopharyngeal microbiome are 
associated with NPC patients’ short-term clinical outcome, which calls for more extensive 
longitudinal studies with long-term follow-up for verification and serves as a base of generating 
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Nasopharyngeal carcinoma (NPC) is one type of malignant head and neck tumors, 
characterized by unique geographic distribution endemic to southern China, Southeast Asia, 
and the Middle East/North Africa. It is widely accepted that the interaction of Epstein-Barr 
Virus (EBV) infection, environmental and lifestyle factors, and genetic susceptibility, 
contributes to NPC carcinogenesis. In the past two decades, extensive application of intensity-
modulated radiotherapy (IMRT) and widespread introduction of chemotherapy with various 
strategies (concurrent, adjuvant, induction) have significantly contributed to a desirable 
prognosis: better survival with less and/or lower level of toxicities. 
However, there are still numerous knowledge gaps in relation to NPC risk and prognosis. The 
ubiquitous EBV infection (mainly persists latently) in over 90% of the world population is 
insufficient to explain the distinct disease burden and makes the primary intervention difficult. 
Monitoring and/or modifying environmental and lifestyle risk factors are reasonable measures 
in disease control and intervention. A progressively declined NPC incidence trend has been 
observed worldwide, partly reflecting a better understanding of the disease, rapid economic 
development, and gradual changes in environment and lifestyle. Nevertheless, epidemiological 
studies in China, especially in southern regions, showed generally stable incidence trends from 
the 1980s to 2010s. 
Currently, the 5-year survival rates of non-metastasis NPC patients are ranging from 60-90%. 
However, around 30% of them will relapse with either recurrent disease or metastasis. There 
is a clear need to identify patients with diverse prognosis and provide optimal local and 
systematic treatments in clinical practice. Beyond the tumor stage, EBV-related markers are 
currently recommended for prognostic risk stratification and therapeutic monitoring in NPC, 
although the evidence in clinical practice is less conclusive. Researches on various biomarkers 
concerning treatment response and disease prognosis are warranted. 
The purpose of this thesis is to study whether dietary habits, oral commensal microbiome are 
associated with NPC risk in southern China, and to explore the longitudinal pattern of 





Nasopharyngeal carcinoma (NPC) occurs in the epithelial lining of the nasopharynx, which is 
part of the pharynx and connects the nasal cavity and oropharynx. The nasopharynx is a box-
like area, under and in front of the base of skull and pharyngeal tonsils, above and behind the 
soft palate, with an opening of the eustachian tube (called pharyngeal recess or Rosenmüller’s 
fossa) on each side (Figure 2.1). NPC frequently rises in the pharyngeal recess [1]. NPC is a 
nonlymphomatous, squamous-cell carcinoma, histologically classified into keratinizing 
squamous cell carcinoma, non-keratinizing carcinoma (undifferentiated and differentiated), 
and basaloid squamous cell carcinoma by World Health Organization [2-4]. The following 
topics regarding NPC will be discussed: descriptive epidemiology, risk factors, clinical 
characteristics, treatment and prognosis, as well as prognosis factors. 
 
Figure 2.1 Anatomy of the nasopharynx (adapted from Hong LL et al. [5]). 
 
2.1 DESCRIPTIVE EPIDEMIOLOGY 
Worldwide, NPC is an uncommon cancer with approximated 129 000 new cases (0.7% of all 
cancers combined) and 73 000 deaths (0.9% of all cancer-related deaths combined) in 2018 
[6]. It is rare in most parts of the world with an age-standardized incidence rate (ASIR) of less 
than 1 per 100 000 person-years (Figure 2.2). However, it is endemic in the East and Southeast 
Asia, South-Central Asia, as well as North and East Africa [6-13]. Around half of the estimated 
new cases were reported in China, with an ASIR (world) of 3.0 per 100 000 person-years [6]. 
Notably, the NPC incidence increases from northern China to southern China with up to 30 per 
100,000 person-years in southern China (e.g., Hong Kong, Sihui in Guangdong province), 
while Tianjin in northern China has less than 2 per 100,000 person-years (Figure 2.3) [10]. 
Males have two to three times higher NPC incidence than females in different populations [6-
12]. Like most cancers, NPC incidence increases with age in the low-risk population. On the 
contrary, the incidence among high-risk population peaks at ages 50 - 64 years following a 
decline afterward [12-15]. Migrant studies have suggested that Chinese immigrants have higher 
NPC incidence than other ethnicities in Malaysia and the United States [16, 17]. Genetic, 
anthropological, and linguistically studies have proposed that NPC might have originated in 
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the Bai-Yue peoples and was transmitted to the Han Chinese in southern China via 
intermarriage [18, 19]. 
 
Figure 2.2 Global nasopharyngeal carcinoma incidence: estimated age-standardized incidence 
rate per 100,000 person-years (both sexes, all age). Data and graph production: GLOBOCAN 
2018, IARC [20]. 
 
Figure 2.3 The geographical distribution of nasopharyngeal carcinoma in China (adopted from 
Tao Q et al. [10]). (a) The mortality rate of NPC among males (world standardized rate; per 
100,000 person-years) in China, 1970s (Data source: http://cancernet.cicams.ac.cn). It is in line 
with incidence of NPC within China, increasing from north to south. (b) The incidence rate 
(per 100,000 person-years) of NPC in males, from selected areas.  
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Gradually declining trends of NPC incidence have been observed in Southern and Eastern 
Asia, North America, and Nordic countries [17, 21-24], which might partly be explained by a 
better understanding of the disease, rapid economic development, and gradual changes in 
environment and lifestyle (e.g., declined exposure to traditional preserved-foods and tobacco 
control) in the last few decades [9, 10, 25]. However, some researchers considered that these 
results need to be viewed cautiously in the context of population shifting due to constant 
immigration, especially in the high-risk regions that underwent dramatic economic 
development in the past 40 years, such as Hong Kong, Singapore, and Guangzhou [10]. 
Notably, some poorly developed areas (e.g., Sihui in Guangdong, and Cangwu in Guangxi; 
Figure 2.4) showed generally stable trends from 1980s to 2010s [10, 26, 27]. Nationwide 
studies analyzing data from more than 250 local population-based cancer registries in China 
reported that NPC incidence was at a high level in 2013 compared to other countries, and no 
apparent increasing or decreasing trend was witnessed [11, 12]. 
 
Figure 2.4 The incidence of nasopharyngeal carcinoma in southern China from 1978 to 2002 
(figure adopted from Tao Q et al. [10]).  
 
2.2 RISK FACTORS 
Around 95% of NPC cases in endemic regions, such as southern China, are non-keratinizing 
type, which has different pathogenesis and risk factors from the keratinizing type [28-30]. This 
section will mainly focus on the risk factors of non-keratinizing NPC, including EBV infection, 
environmental and lifestyle factors, as well as genetic susceptibility. 
2.2.1 EBV infection 
Epstein-Barr virus, also known as human herpesvirus 4, is a linear double-stranded 
deoxyribonucleic acid (DNA) virus and the first human tumor virus discovered [31]. It is the 
most widely spread and persistent virus infection known in humans, with over 90% world 
population sustaining an asymptomatic life-long infection [32]. EBV primarily infects human 
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oropharyngeal epithelium via saliva (lytic infection) very early in life with no or minor 
symptoms. In contrast, a small proportion of people with delayed primary infection may result 
in infectious mononucleosis [33-35]. In any case, EBV is programmed to be a life-long latent 
infection in the human memory B-cell pool afterward [36-40].  
EBV, including but not limited to its genome, compositions, antigens, is found virtually in all 
non-keratinizing NPC [41-47] but hardly detected in the normal nasopharyngeal epithelium 
[47, 48]. EBV-related NPC constitutes more than 95% of the cases in endemic regions, but less 
than one-third of NPC in non-endemic regions [37, 49-51]. However, the question about how 
a ubiquitous virus causes endemic cancer only in certain parts of the world has not yet been 
answered.  
The latent infection of EBV in epithelial cells is abnormal [33, 34, 52]. It remains unclear how 
EBV enters the nasopharyngeal epithelium and establishes a latent infection, as well as how 
latent EBV contributes to the NPC carcinogenesis. Currently, several key receptors have been 
found involved in the process of EBV entering (neuropilin 1 [53], epidermal growth factor [54], 
integrins and non-muscle myosin heavy chain IIA [55], ephrin receptor A2 [56, 57]); two high-
risk EBV variants associated with endemic NPC in southern China have also been identified 
[58]. In addition, researchers have established immortalized nasopharyngeal epithelial cells 
with type II EBV latency, which may be useful models for the study of EBV infection and its 
role in NPC development [59]. 
2.2.2 Environmental and lifestyle factors 
2.2.2.1 Dietary factors 
The World Cancer Research Fund concludes in their Expert Reports of the Continuous Update 
Project (CUP) that the consumption of Cantonese-style salted fish is a probable cause of NPC 
[60, 61]; and the International Agency for Research on Cancer (IARC) has also classified 
Cantonese-style salted fish as a carcinogen [62, 63]. In the 1960s, researchers first reported an 
association between Chinese-style salted fish and NPC risk among Tankas (boat dwelling 
Cantonese) in Hong Kong [64]. Afterward, various epidemiological studies among different 
populations consistently demonstrated similar associations (in Hong Kong [65]; Guangzhou 
[66]; Cangwu [67]; Shanghai [68]; Tianjin [69]; Guangdong [70]; Guangxi [71]; Taiwan [72]; 
southern China [73]; and Malaysian Chinese [74]). These studies also reported stronger 
associations with NPC risk among people who consumed salted fish during childhood, 
especially during weaning (salted fish pre-chewed by parents has been used as a traditional 
weaning food in south China), than for consumption during older ages. Similarly, the CUP 
Reports indicated strong dose-response associations across different age periods (risk ratio 
[RR]: 1.28 [1.13-1.44] in adulthood; 1.32 [1.14-1.60] at age 10; 1.42 [1.11-1.81] at ages 0-3) 
[60, 61]. Cantonese-style salted fish is produced using less salt and a higher degree of 
fermentation than other types of preserved fish, and is favorable to bacterial growth, such as 
Staphylococci, facilitated by the high outdoor temperatures and air humidity in southern China 
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[75-77]. It has been found to be rich in N-nitroso compounds that have been associated with 
cancer development in experimental studies [77-79]. 
The CUP reports also provide evidence that intake of preserved non-starchy vegetables, 
processed meat, and red meat are associated with increased risk of NPC, while increased 
consumption of fresh non-starchy vegetables and fruits is associated with decreased risk of 
NPC [61, 80-82]. In addition, several studies have suggested that milk consumption may be a 
protective factor for NPC [83-85], although, conflicting results exist [86, 87]. 
It is noticeable that, along with the rapid economic development in the endemic areas since the 
second half of the 20th century, dietary habits have significantly and progressively changed 
over time: decreased consumption of preserved foods (especially Cantonese-style salted fish),  
increased intake of fresh foods, and the fact that the habit of weaning with salted fish has 
become rare [22, 88]. However, this is not reflected in the relatively stable NPC incidence in 
southern China over the past decades [12, 26, 27]. Theoretically, this may imply that some of 
the dietary risk factors primarily in early life affect disease development, and an expected 
decrease in NPC incidence might emerge in about 4 - 5 decades afterwards. Data on NPC 
incidence from the endemic areas, especially southern China, in the coming two decades is 
therefore crucial. 
On the other hand, given the substitution effects in dietary behavior, high consumption of some 
food items is generally related to low intake of other food items [89]. Focusing on single food 
items is insufficient for understanding the potential impact of dietary habits, namely how 
people choose to combine their foods, on the disease risk. Nonetheless, to our knowledge, the 
potential association between dietary habits and NPC risk is unclear. 
2.2.2.2 Tobacco smoking and alcohol intake 
IARC classifies tobacco as a group I carcinogen [63]. Tobacco smoking has been suspected as 
a risk factor for NPC and investigated by numerous epidemiological studies in both endemic 
and non-endemic areas [73, 90-96]. However, the results have been contradictory. Recently, 
two meta-analyses indicated an increased NPC risk among smokers compared to non-smokers, 
despite substantial heterogeneity among the included studies [97, 98]. Alcohol consumption 
has also been studied for years, and it seems not to be associated with NPC risk. Although some 
studies observed a J-shape association [99-101], most observational studies found null results 
[9, 95, 102-104]. Therefore, meta-analysis using individual participant data from observational 
studies are warranted to better understand the association of tobacco smoking and alcohol 
intake with NPC risk.   
2.2.2.3 Oral hygiene 
Poor oral hygiene has long been implicated as a risk factor for various cancers, such as oral 
cancer, esophageal cancer, and gastric cancer [105-108]. Poor oral hygiene indicates dysbiosis 
in the oral microbiome, which has been linked to head and neck cancers, colorectal cancer, and 
pancreatic cancer [109-112]. A recent study in southern China has shown a positive association 
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between NPC risk and the number of repaired teeth and NPC risk, while daily frequency of 
teeth brushing was inversely related with NPC risk [113]. Although little is known about the 
underlying mechanism, it is suspected that dysbiosis in the oral microbiome indicated by poor 
oral health might facilitate EBV reactivation via oncogenic metabolites (e.g., butyric acid, 
nitrosamines), and/or conduce partly to the heavy infiltration of non-malignant lymphocytes 
around malignant epithelial cells [109, 114-119]. It is noteworthy that several potential NPC 
risk factors mentioned above, such as tobacco smoking and diet, may affect oral hygiene and 
oral microbiome [120-124]. Thus, a well-designed, exploratory study is needed to study the 
association between the oral microbiome and NPC risk, with careful handling of potential 
confounding. 
2.2.2.4 Other factors 
Occupational exposure to fumes, smokes, wood/cotton dust, asbestos, and formaldehyde has 
been linked to increased risk of NPC [67, 73, 125-129], though no consensus has been 
established. Additionally, living conditions, residential history, use of wood fuel (smoke), 
education level, and socioeconomic status have also been investigated; however, results vary 
across studies. One concern is that those factors seem to correlate with each other tightly and 
are hard to measure properly. 
2.2.3 Genetic susceptibility 
Genetic susceptibility is another essential factor in NPC etiology, supported by a series of 
scientific researches addressing NPC's familial clustering since the 1970s. Later on, this 
phenomenon has been well documented across different populations [130-135]. A recent case-
control study in southern China reported a more than fourfold higher NPC risk among 
individuals with first-degree relatives diagnosed with NPC [136]. Meanwhile, researchers have 
committed to reveal the basis of familiar clustering by demonstrating the connection between 
NPC susceptibility and genomic polymorphisms [30, 137, 138]. Numerous studies have 
reported that the most influential factors were located in the human leukocyte antigen (HLA) 
region on chromosome 6p21 [139-141]. Recent genome-wide association studies with large 
sample sizes mainly from the endemic areas have identified more loci (HLA-A, HLA-B, HLA-
C, HLA-DQA1, HLA-DQB1, HLA-DRB1, HLADPB1, and HLA-F) strongly associated with 
NPC risk [140, 142-147]. Benefitting from the substantial development of genomic analysis, 
several studies from southern China have extensively demonstrated more candidate genes other 
than HLA loci associated with NPC risk (including MECOM, TNFSFR19, CDKN2A/B, TERT 
[143, 148-150], human macrophage-stimulating 1 receptor (MST1R) [151], and ITGA9 [152]). 
To date, the search for determinants of NPC susceptibility and the investigation of the 
biological mechanism are ongoing to understand NPC's genetic susceptibility fully. 
2.2.4 Early-life exposure 
The familial aggregation of NPC might result from inherited genetic susceptibility and shared 
environmental and lifestyle factors (e.g., living conditions, diet, oral health, and socioeconomic 
status), respectively, or jointly. As previously described, researchers have consistently 
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observed a stronger association of NPC risk with salted-fish intake during an earlier lifetime. 
Some have suggested that the weaning habit might be a critical mechanism for EBV's initial 
infection in China [153]. Moreover, exposure to passive smoking during childhood has been 
reported to be independently associated with increased NPC risk in never-smoking men and 
women [96]. Accordingly, it is reasonable to hypothesize that a person carrying high-risk HLA 
allele(s), infected with high-risk EBV strains (most likely caught it from family member) in 
early life, harboring a certain pattern of oral/nasopharyngeal microbiome, exposed to specific 
carcinogen/chemical (such as N-nitrosamine rich in salted fish or other preserved foods), may 
have a substantially higher risk of non-keratinizing NPC in endemic regions.  
However, numerous open questions remain: is a person carrying high-risk HLA allele(s) 
especially susceptible to high-risk EBV strains? Does the oral/nasopharyngeal microbiome 
contribute to EBV genotype selection pressures? Does the oral/nasopharyngeal microbiome or 
specific chemicals contribute to EBV entry into epithelial cells and the establishment of latent 
infection? Are tobacco smoking, preserved food consumption, and dietary habits involved in 
NPC risk or general cancer risk?  
Nevertheless, to test the hypothesis of early-life exposure and to address all these questions, a 
well-designed, large-scale birth cohort with more than 50 - 60 years of follow-up in endemic 
areas is needed, which is generally difficult, if not impossible. Besides, the lack of a feasible 
and reliable non-keratinizing NPC model is another difficulty and hamper. 
2.3 CLINICAL CHARACTERISTICS 
Because of the deep-seated anatomical location, most NPC patients present non-specific 
symptoms when the disease is initiated. NPC’s clinical presentation is correlated with the 
anatomical structures being invaded as the primary tumor growth and varies accordingly 
(Figure 2.1) [5, 25]. NPC usually occurs in the pharyngeal recess and invades surrounding 
structures. Thus, patients can develop epistaxis (post-nasal drip with blood), nasal obstruction, 
and discharge when the tumor presents in the nasopharynx and/or anteriorly spreads to the nasal 
cavity, pterygoid fossa, and maxillary sinuses. Dysfunction of the eustachian tube (e.g., 
tinnitus, secretory otitis media, and deafness) indicates the paranasopharyngeal space invasion. 
Palsy of cranial nerves (the III, V, VI, XII cranial nerves being most affected), presenting as 
diplopia, facial pain and numbness, and headache, implies an advanced disease locally in which 
the tumor superiorly and posteriorly erodes the base of the skull, clivus, and intracranial 
structures. Neck masses, usually appearing in the upper neck, point to a regional spread of the 
tumor. In the clinic, painless neck mass is the most common symptom among newly diagnosed 
NPC patients (76%), followed by nasal dysfunction (73%), aural dysfunction (62%), headaches 
(35%), and diplopia (11%) [154]. Around 80% of the patients present with multiple symptoms, 
while 20% report a single symptom or no symptom (1%). 
Clinical assessments shall be administrated to patients with symptoms. Nasopharyngoscopy is 
routine for detecting a suspected nasopharyngeal mass; meanwhile, an endoscopic biopsy is 
necessary for definitive histopathological diagnosis of NPC. Imaging modalities, such as 
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magnetic resonance imaging (MRI), computed tomography (CT), and ¹⁸F-fluorodeoxyglucose-
positron emission tomography/computed tomography (¹⁸F-FDG-PET/CT), are commonly used 
for assessing the tumor size and location and evaluating the stage of NPC.  
The Union for International Cancer Control /American Joint Committee on Cancer 
(UICC/AJCC) TNM (tumor-node-metastasis) staging system, 8th edition (in 2016), is the most 
important and widely used staging guideline for NPC [155-157]. Given the deep-seated 
anatomical location and aggressive behavior, more than 75% of NPC patients have advanced 
disease with either local or regional spread (stage III and IV) and around 10% with distant 
metastasis at diagnosis [13, 29, 30, 154, 158], making effective treatment challenging. 
2.4 MANAGEMENT AND PROGNOSIS 
Primary NPC is radiosensitive. Radiation therapy (RT) is the mainstay of curative-intent 
treatment for non-disseminated NPC, instead of surgery and chemotherapy [13]. At present, 
most cancer centers have achieved five-year overall survival (OS) rates around 60%-80% for 
non-metastatic patients with radiotherapy +/- chemotherapy. However, around 30% of NPC 
patients will suffer from distant metastasis and resistant/recurrent disease, resulting in a poor 
prognosis with 5-year OS rate lower than 40%. 
2.4.1 Treatment for non-metastatic NPC 
Currently, intensity-modulated radiotherapy (IMRT) is the most widely used radiation 
technique [13]. IMRT provides full coverage of the complex-shaped gross tumor and 
subclinical diseases with precise dose delivery while minimizing the dose to critical organs at 
risk by controlling the intensity of the radiation beam. IMRT is superior to conventional 
radiotherapies (e.g., two-dimensional radiotherapy, three-dimensional conformal radiotherapy) 
with significant improvement in survival and reduction of radiation-related toxicities among 
non-metastatic NPC patients [159-169]. At present, there is little doubt that IMRT alone is the 
standard of care for stage I NPC (Table 2.1), with expected 5-year disease-specific survival 
(DSS) and OS over 95% [170].  
The use of chemotherapy as part of the management for advanced locoregionally diseases, 
especially concurrent chemotherapy during radiotherapy, is another crucial progress. 
Compelling and consistent evidence from numerous clinical trials and meta-analyses has been 
demonstrated the survival benefit of concurrent chemoradiotherapy among NPC patients with 
stage III to IVb disease, with absolute survival benefits of around 6% at 5 years [171-179]. 
However, the benefits of adjuvant and induction chemotherapy as a combination treatment for 
stage II to IVb disease, beyond the concurrent chemoradiotherapy, are still being discussed [25, 
30, 178-180]. Current viewpoints propose that adjuvant chemotherapy cannot lead to better 
survival alone and may not achieve further survival benefits incorporating concurrent 
chemoradiotherapy, while induction chemotherapy, on top of concurrent chemoradiotherapy, 
may contribute to improving distance control and survival in the IMRT era [13]. Nonetheless, 
the latest version of the National Comprehensive Cancer Network (NCCN) Guidelines 
(Version 2.2020; Jun 9, 2020) recommends concurrent chemoradiotherapy ± sequential 
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chemotherapy for a broad range of NPC diseases: from stage II to IVb (Table 2.1) [181]. It 
means that the decision-making for patients with stage II to IVb diseases depends primarily on 
experienced experts or the clinical trials they participated in (if available). The ambiguous 
recommendations for this group of NPC patients remain to be improved by a better prognostic 
risk stratification model and therapeutic monitoring for providing more accurate clinical 
practice guidelines. 
Table 2.1 Treatment strategies for NPC with different stages 
Stage (8th ed. a) NCCN (V2.2020 b) 
  Stage I Radiotherapy alone 
  Stage II 
  Stage III 
  Stage IVA - B 
Radiotherapy plus 
    concurrent chemotherapy + adjuvant chemotherapy (2A c) 
or induction chemotherapy + concurrent chemotherapy (2A)                  
or concurrent chemotherapy (2B) 
  Stage IVC Chemotherapy alone or radiotherapy + chemotherapy 
a  Stage system: American Joint Committee on Cancer (AJCC) – TNM Staging System (8th ed. 2016) 
b National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2020 
c NCCN Categories (1-3) of Evidence and Consensus 
 
2.4.2 Management of residual/recurrent and metastatic NPC 
Residual/recurrent and metastatic diseases in NPC are not uncommon and present poor 
outcomes [164-169, 182-185]. Thus, post-treatment surveillance is essential and critical for 
NPC patients. The first clinical check-up for evaluating a patient’s treatment response usually 
takes place 10-12 weeks after the completion of radiotherapy, including physical examination, 
nasopharyngoscopy, and radiation imaging tests (MRI/CT/PET-CT, etc.) [30, 186, 187]. 
NCCN guidelines provide detailed follow-up strategies.  
After primary treatment, around 10-15% of NPC patients will experience residual/recurrent 
disease, and up to 20% will develop distant failure [165, 167, 168, 182-185]. It has been 
reported that up to 40% of the T4 disease experienced treatment failure [165, 188-190]. Salvage 
surgery is recommended for residual neck mass and a resectable tumor which relapses within 
one-year after primary radiotherapy [191, 192]. Tumors recurring more than one year after 
initial treatment are considered for re-irradiation [193]. Taking systematic therapy 
(cisplatin/gemcitabine are first-line regimens) or participating in clinical trials may otherwise 
be regarded [181]. Current studies report a similar 5-year OS rate of 40% among NPC patients 
treated with neck dissection or re-irradiation [192, 193]. Nonetheless, aggressive salvage 
treatments involve inevitably acute and late toxicities, impacting the survivors’ quality of life 
significantly. On the other hand, it is recommended for patients with metastatic disease to 
participate in feasible clinical trials, as preferred. Palliative chemotherapy is alternatively 
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recommended with cisplatin plus gemcitabine as first-line regimens. Prognosis of metastatic 
NPC varies greatly with an OS of approximately 12 to 20 months and a 5-year OS rate lower 
than 40% [194-197]. 
Tumor immunotherapy is a rising star in cancer treatment. Theoretically speaking, NPC 
patients may be eligible for immune checkpoint blockade therapies due to high programmed 
death-ligand 1 (PD-L1) expression and abundant infiltration of non-malignant lymphocytes 
around the primary tumor [198-201]. Several single-arm trials evaluating immunotherapy 
targeting the PD1/PD-L1 pathway in recurrent/metastatic NPC patients have shown promising 
outcomes [202-204]. Some ongoing phase 2/3 trials, investigating the immunotherapies 
targeting EBV and/or PD1/PD-L1 on managing locoregional, recurrent, and metastatic NPC, 
are anticipated to provide useful evidence [13].  
2.4.3 Prognostic factors 
The anatomical TNM stage is considered the pivotal factor for guiding treatment strategy and 
prognostic stratification. Besides, compelling evidence has shown that a pretreatment EBV-
DNA test can provide further prognostic information and assist the assessment of treatment 
response; meanwhile, a post-treatment EBV-DNA involves in the surveillance of locoregional 
failure and distant metastasis in a high-risk population [205-211]. Currently, the NCCN 
guideline (Version 2.2020) recommends considering plasma EBV-DNA for therapeutic 
monitoring. However, several vital concerns remain: EBV-DNA is not 100% detectable among 
NPC patients [212]; large variabilities in the detection of plasma EBV-DNA have been reported 
across skilled laboratories [213] and a harmonized quantitative protocol/assay for EBV-DNA 
detection is not yet available; plasma EBV-DNA levels may be affected by EBV-infected B 
cells [30]. There is a clear need to search for reliable and effective prognostic markers in NPC 
management. 
Recently, the human commensal microbiome has been reported to be shaped by anticancer 
treatment and to modulate the host’s clinical response to treatment (e.g., CpG-oligonucleotide, 
gemcitabine, and immune checkpoint inhibitors) [214-218]. Two recent studies demonstrated 
severe compositional and functional imbalance in the gut and oral microbial communities after 
radiotherapy among cancer patients, which may contribute to the pathogenesis of therapy-
induced gastrointestinal and oral mucositis [219, 220]. Similar to the intestinal tract and oral 
cavity, the human nasopharynx harbors diverse microbes. It is reasonable to suspect that 
aggressive radiotherapy might induce a dysbiosis of the nasopharyngeal microbiome among 
NPC patients. Yet, no data is available, and little is understood whether the commensal 
microbiome is associated with the host’s response to radiotherapy [221]. 
In the modern IMRT era, a promising prognosis can be achieved by incorporating 
chemotherapy among the majority of NPC patients, leaving 30% of them suffering from poor 
outcomes due to treatment failure. Therefore, it is essential to build an effective strategy based 
on crucial prognostic stratification and therapeutic monitoring in the initial treatment to 
improve therapeutic outcomes and avoid unnecessary salvage.  
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3 AIMS AND RESEARCH QUESTIONS 
By studying a range of topics concerning nasopharyngeal carcinoma in the endemic area, this 
thesis aimed to provide more insights into the disease in terms of risk factor and prognosis. 
Specifically, we investigated whether dietary habits were associated with NPC risk in southern 
China, using a population-based case-control study. Among a subset of the case-control study, 
we studied whether oral microbiome was associated with the risk of NPC. We also conducted 
a longitudinal hospital-based NPC cohort study in southern China to deliver a proof-of-concept 
data on the patterns of the commensal microbiome in patients’ nasopharynx during 
radiotherapy and their role in NPC prognosis (Figure 3.1). 
 
Figure 3.1 Overview of three studies in this thesis. (NPC, nasopharyngeal carcinoma; NP, 






4 METHODS & MATERIALS 
Table 4.1 shows an overview of the study designs, study population, main measurements, and 
statistical methods used for each paper in the thesis. 
 
Table 4.1 Overview of methods and materials of each paper in this thesis. (NPCGEE: Gene-
environment Epstein-Barr Virus Interactions in the Etiology of nasopharyngeal carcinoma; 
NPC: nasopharyngeal carcinoma; PCoA; principal coordinates analysis; PERMANOVA: 
permutational multivariate analysis of variance; ANCOM: analysis of composition of 
microbiome; GXMU: Guangxi Medical University; RT: radiation therapy; NMIT: non-
parametric microbial interdependence test; SS-ANOVA: smoothing-spline analysis of 
variance). 
 
4.1 STUDY DESIGN, STUDY POPULATION, AND DATA COLLECTION 
4.1.1 Population-based NPC case-control study in southern China 
A population-based NPC case-control study, entitled “Gene-environment Epstein-Barr Virus 
Interactions in the Etiology of nasopharyngeal carcinoma (NPCGEE) project,” was launched 
in southern China, 2010 [222]. People officially residing in 13 cities/counties in Wuzhou, 
Guiping, and Pingnan areas in Guangxi Autonomous Region, and Zhaoqing area in Guangdong 
Province, were defined as study area for the NPCGEE project (Figure 4.2). From 2010 to 2013, 
3,047 newly diagnosed NPC patients aged 20-74 were identified and invited; 83.8% of them 
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(2,554) participated. The enrollment was closed by November of 2014, when 2,648 (82.7%) 
controls consented to participate, among 3,202 who were frequency-matched with the NPC 
cases on age (in five-year groups), sex, and residential region. 
A team of trained interviewers performed face-to-face interviews with all NPC cases and 95% 
population controls (5% interviewed by phone) using a computerized questionnaire [222]. 
During the structured interview, information on demographics and known potential NPC risk 
factors, including family history of cancer [136], residential history, occupational history, 
smoking habits [96], alcohol drinking, herbal tea and soup consumption [223], and dietary 
habits was collected [224]. Biosamples (including blood and saliva) were collected at the 
interview (not available for the participants interviewed by phone). Specifically, participants 
were required not to eat or chew gum 30 minutes before saliva collection. Saliva samples (2ml) 
were collected into 50ml tubes with a Tris-EDTA buffer, transferred by cold-chain (-20 ºC) 
within 3 days, and stored at -80 ºC until further use. 
In total, 2,554 NPC cases and 2,648 controls were included in Study I, while a subset from 
Wuzhou area (Wuzhou subset: 532 cases and 534 controls) was included in Study II. 
 




4.1.2 Prospective NPC patient cohort 
A hospital-based prospective cohort of NPC patients was recruited in the First Affiliated 
Hospital of Guangxi Medical University, Guangxi Autonomous Region, China. Between 2014 
and 2015, 62 newly diagnosed, treatment naïve, non-metastatic NPC patients were enrolled in 
Study III (Figure 4.3). All of them were treated according to the standard of care (radiotherapy 
± concurrent chemotherapy ± adjuvant/induction chemotherapy ± other treatments; according 
to NCCN guidelines). During radiotherapy (7 to 8 weeks), successive nasopharyngeal swabs 
were repeatedly collected, specifically, starting from treatment-naïve (S0), twice a week 
afterwards until the completion of radiotherapy, and at the completion of radiotherapy (SE). 
The sampling time points correspond to an accumulated dose of radiation. 
The first clinical check-up evaluating patients’ treatment response (based on the response 
evaluation criteria in solid tumors, RECIST) [225, 226] was performed three months after the 
completion of radiotherapy.  
 
Figure 4.3 Study design and sample collection in the prospective cohort of nasopharyngeal 
carcinoma patients. (GXMU, Guangxi Medical University; CR, complete response; PR, partial 
response; SD, stable disease) 
 
4.2 MAIN MEASUREMENTS 
4.2.1 Dietary intakes 
The association between dietary intakes from two life periods and NPC risk was investigated 
in Study I. During a structured interview, dietary intake information of all participants in the 
NPCGEE project was assessed by a food frequency questionnaire (FFQ) including 77 of the 
most commonly consumed foods in the study area (estimated to cover ca. 80% of total energy 
intake, TEI) [224]. Study participants were asked to provide the frequency of each food item 
(daily, weekly, monthly, yearly, or never) and its estimated portion size (converted into gram 
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later) in two life periods: 10 years before the interview (i.e., adulthood) and at ages 16-18 years 
(i.e., adolescence, for subjects aged above 35 years at the interview). Interviewers used an 
illustrated booklet with pictures of serving sizes of various food items to assist participants in 
estimating the portion size correctly. Individual alcohol consumption and household cooking 
oil intake were collected only 10 years ago, not in adolescence. Therefore, the daily TEI in 
adulthood was calculated from the 77 food items, cooking oil (on household average), and 
alcohol intake if applicable. Daily TEI in adolescence was solely considered energy from the 
77 food items. Chinese food composition tables were used as the base of energy estimation 
[227]. 
4.2.2 Oral microbiome 
A total of 1066 saliva samples derived from the Wuzhou subset of the NPCGEE project were 
used for evaluating the oral microbiome among NPC cases and controls in Study II. 
We used a conserved marker gene, namely 16S ribosomal ribonucleic acid (rRNA) gene, which 
contains one or more highly variable regions as “fingerprint identification” to profile the oral 
microbial communities [228]. Lab processing included DNA extraction and targeted 16S 
rRNA amplicon library preparation, which was implemented in collaboration with Guangxi 
Medical University (China). Salivary DNA was extracted using a protocol with two steps: 1) 
processed by lysozyme and bead beating, 2) applied to the TIANamp blood DNA kit (Tiangen, 
Beijing, China). The 16S rRNA library was prepared using a two-step polymerase chain 
reaction (PCR) strategy: 341F/805R primers (341F-CCTACGGGNGGCWGCAG, 805R-
GACTACHVGGGTATCTAATCC) targeting the variable region 3 to 4 were used for PCR-
round 1, and the sample-specific barcode was added during PCR-round 2 [229, 230]. The 
library cleanup was performed using an Agencourt AMPure XP purification kit. Negative 
controls (water control) and mock communities (known bacterial DNA) were used in DNA 
extraction and 16S library preparation. The quality and quantity of cleaned libraries were 
measured on an Agilent 2100 Bioanalyzer system and real-time PCR. In total, 1080 sample-
libraries were submitted to the Beijing Genome Institute (BGI) using a 2x300-bp paired-end 
strategy on an Illumina MiSeq. 
Afterward, the raw amplicon-sequences from 1066 samples were processed to classify the oral 
microbiome into a feature table, taxonomy, and phylogeny (Figure 4.4). In brief, we used 
Deblur to resolve sequencing data into exact sequence feature (amplicon sequence variants, 
ASVs) based on sequencing error profiles [231]. For taxonomy (a taxonomic name is assigned 
to an ASV), we used a naïve Bayesian classifier trained against the August 2013 Greengenes 
database (q2-feature-classifier in QIIME 2, 2018 November release) [232-234]. Furthermore, 
the same reference was used to build a phylogenetic tree using fragment insertion (99% identity 
tree backbone with q2-fragmentinsertion) [235]. 
4.2.3 Nasopharyngeal microbiome 
Eight hundred seventy nasopharyngeal swabs were collected from 62 NPC patients for 
quantifying the longitudinal patterns in the nasopharyngeal microbiome during radiotherapy-
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based treatment in Study III. The same lab procedure and bioinformatic workflow for sample 
preparation and feature extraction as in Study II was used (Figure 4.4).   
 
Figure 4.4 Overview of the bioinformatics workflow in Study II and Study III. 
 
4.2.4 Treatment outcome of NPC patients 
In Study III, all NPC patients received radiotherapy, with or without sequential chemotherapy. 
All patients were recommended for a clinical check-up at three months after the completion of 
radiotherapy to assess their response status using RECIST criteria (by three oncologists). A 
short-term clinical outcome in this study was defined as: a patient who achieved a CR at the 
check-up was an early responder to radiotherapy-based treatment, otherwise a late responder. 
4.3 STATISTICAL ANALYSES 
4.3.1 Dietary patterns and NPC risk 
In Study I, principal component analysis (PCA) was implemented to identify underlying dietary 
patterns. First, the 77 individual food items were classified into 18 food groups based on food 
group characteristics, similarity of nutrient contents, and prior knowledge [236, 237]. The sum 
of the absolute intake of each food group was calculated as the intake of the corresponding 
food items (in gram). In the PCA procedure, principal components were selected based on a 
scree plot of the eigenvalues. Component scores were computed for each study subject for 
downstream analysis. Dietary components were identified separately for the two study periods 




The associations between the identified dietary patterns and NPC risk were estimated by odds 
ratios (ORs) and the corresponding 95% confidence intervals (CIs) derived from unconditional 
logistic regression models, in Study I. Each component score was transformed to quartiles 
before being entered into the regression models; all identified components were included in the 
models simultaneously. Variables of age (in 10 years group), sex, and residential region were 
considered in the minimally adjusted models; additionally, multiple covariates known or 
suspected to affect both diet and NPC risk based on prior knowledge or findings from the 
NPCGEE project were also included in the fully adjusted models. The ORs and 95% CIs were 
estimated separately for the two study periods.  
A subset of 4215 subjects who provided dietary information in both adolescence and adulthood 
were further investigated in a joint analysis. All dietary components classified in both periods 
were included in the models simultaneously. The same sets of covariates were used as before. 
Moreover, a variable representing birth before or after year 1963 (according to the median age 
of the study population) was used to evaluate potential effect modification by age. This variable 
was included in regression models together with an interaction term. 
4.3.2 Oral microbiome and NPC risk 
The statistical analyses used to study the association between oral microbiome and NPC status 
in Study II are illustrated in Figure 4.5. 
 
Figure 4.5 Biostatistics workflow in Study II. 
 
4.3.3 Longitudinal patterns of the nasopharyngeal microbiome among NPC 
patients during radiotherapy 
Figure 4.6 shows the statistical analyses used for profiling the change of nasopharyngeal micro-
biome among NPC patients during radiotherapy-based treatment and for estimating the 













5 MAIN FINDINGS 
5.1 DIETARY PATTERNS ARE ASSOCIATED WITH NPC RISK 
We analyzed a total of 4398 study participants (2174 NPC cases and 2224 controls) with 
adolescence dietary data and 4832 participants (2387 NPC cases and 2445 controls) with 
adulthood dietary data in Paper I. In both analytical periods, we characterized four dietary 
components among controls and summarized them as four dietary patterns: “balanced diet”, 
“plant-based diet”, “preserved/salted diet”, as well as “animal-foods-based diet” (Figure 5.1). 
 
Figure 5.1 Component loadings of dietary patterns during adolescence and adulthood 
 
In Table 5.2, the ORs of four dietary patterns derived from fully adjusted models in two life 
periods are listed. Among participants who had the highest quartiles of the “plant-based diet”, 
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a 34% decreased NPC risk in adolescence (ORq4 vs. q1 = 0.66, 95% CI = 0.52 – 0.84, Ptrend = 
0.0067) and a 50% decreased risk in adulthood (ORq4 vs. q1 = 0.50, 95% CI = 0.41 – 0.63, Ptrend 
< 0.0001) were observed. On the contrary, increased NPC risk was found along with increased 
quartiles of the “animal-foods-based diet” in both periods, although the effect in adolescence 
was smaller than in adulthood (adolescent: ORq4 vs. q1 = 1.39, 95% CI = 1.13 – 1.70, Ptrend = 
0.0002; adulthood: ORq4 vs. q1 = 2.26, 95% CI = 1.86 – 2.75, Ptrend < 0.0001). Weak associations 
were observed between NPC risk and the “preserved/salted diet”, while no evident association 
was found between the NPC risk and the “balanced diet”. Besides, we studied 4215 participants 
with diet information in both period in a joint analysis which included eight age-specific dietary 
patterns simultaneously. Remarkably, the OR estimates of adulthood diet in association with 
NPC risk remained largely unchanged after adjusting for adolescent diet (for “plant-based 
diet”: ORq4 vs. q1 = 0.49, 95% CI = 0.37 – 0.65; for “animal-foods-based diet”: ORq4 vs. q1 = 2.20, 
95% CI = 1.75 – 2.77). In contrast, following adjustment for adulthood diet, the previous 
associations of NPC risk and adolescent dietary patterns were moderated. 
Table 5.2 Odds ratios of nasopharyngeal carcinoma by quartiles intake of four dietary patterns 
in adolescence and adulthood 
 
Adolescence a  (N=4398) Adulthood b  (N=4832) 
Dietary pattern OR (95% CIs) Ptrend OR (95% CIs) Ptrend 
Balanced diet 
    
  Quartile 1 (ref.) 1.0 (ref.) 0.3245 1.0 (ref.) 0.9901 













    
  Quartile 1 (ref.) 1.0 (ref.) 0.0067 1.0 (ref.) <.0001 













    
  Quartile 1 (ref.) 1.0 (ref.) 0.0011 1.0 (ref.) 0.0207 













    
  Quartile 1 (ref.) 1.0 (ref.) 0.0002 1.0 (ref.) <.0001 














Abbreviations: OR, odds ratio; CIs, confidence intervals; ref., reference. 
a Adolescence analysis: estimates from multivariate logistic regression models were adjusted for age (10-years groups), sex, 
residential area, body mass index, total energy intake, education level, current housing type, current occupation, smoking 
status, NPC history among first-degree relatives, number of filled tooth, frequency of tooth-brushing, frequency tea 
consumption, weekly frequency of soup consumption, and herbal tea consumption, and quartiles of the daily total energy 
intakes in adolescence. Results referred to the composite model fitting all the four dietary components simultaneously. 
b Adulthood analysis: estimates from multivariate logistic regression models were adjusted for the same set of co-variates as 
in adolescence, the quartiles of adulthood TEI was used instead of adolescent TEI. 
 
5.2 ORAL MICROBIOME IS ASSOCIATED WITH NPC RISK 
We analyzed 994 participants (499 NPC cases, 494 controls) enrolled in the Wuzhou region of 
the NPCGEE project in Paper II [238]. 
In the global comparisons of alpha diversities regarding the mean species diversity in a 
community, we observed significantly fewer amplicon sequence variants (ASVs) (P-value < 
1x10-12, Figure 5.2 a), as well as reduced Faith’ phylogenetic diversity and reduced Shannon 
diversity among NPC cases. We also found significant differences in beta diversities (scale the 
level of pairwise dissimilarity) between NPC cases and controls, based on unweighted UniFrac 
(Figure 5.2 d), weighted UniFrac, and Bray-Curtis distance (PERMANOVA, false discovery 
rate [FDR] adjusted P-value < 0.001, 9,999 permutations). We noticed that NPC status was 
accounted for the largest variation explained in the unweighted UniFrac distance (Figure 5.2 b), 
while it was the second largest  in weighted UniFrac distance following smoking (Figure 5.2c). 
 
Figure 5.2 The oral microbiome differs between nasopharyngeal carcinoma cases and controls. 
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On the other hand, we identified 51 ASVs out of 245 abundant ASVs (relative abundance larger 
than 0.02% and present in more than 10% of 994 samples) which presented more in controls 
(log-binomial model adjusted for age, sex, sequencing run, residential community, and oral 
health, FDR P-value < 0.05; Figure 5.2 e). In contrast, two ASVs among 245 abundant ASVs 
showed more prevalent in NPC patients: a member of the genus Granulicatella ASV (Gran-
7770) and a Lactobacillus ASV (Lact-eca9). We also observed that the Gran-7770 was 3.4 
times more abundant among NPC cases than in controls (95% CI = 2.4 - 4.9), and a second 
Granulicatella ASV (Gran-5a37) was less abundant in cases. In addition, we found that all 
participants carried at least one or more Granulicatella species. Among them, 972 (97.8%) 
only carried three Granulicatella ASVs: Gran-5a37 and Gran-7770 (both mapped to species 
Granulicatella adiacens), and Gran-6959 (Granulicatella elegans) (Figure 5.3 a). Based on 
multinomial logistic regression, the variants of Granulicatella adiacens a participant carried 
were significantly associated with their NPC status (case or control). NPC cases presented 
higher odds of having both ASVs, and even higher odds of carrying Gran-7770 alone, 
compared to carrying Gran-5a37 alone (Figure 5.3 b). We found clear separations in principal 
coordinates analysis (PCoA) space in weighted and unweighted UniFrac and Bray-Curtis 
distances comparing samples carrying Gran-7770, both, or Gran-5a37, which was statistically 
highly significant (PERMANOVA, P-value < 0.001, 999 permutations; Figure 5.3 c). 
 
Figure 5.3 The Granulicatella adiacens variant predicts community structure. 
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Furthermore, we distinguished five networks using SparCC-based network analysis. Among 
them, a large network with 29 co-occurring and co-excluding ASVs caught our attention 
(Figure 5.4). In this network, Gran-7770 and Gran-5a37 each formed co-occurring nodes with 
a dozen ASVs, which were exclusive. By BLAST (basic local alignment search tool) searching 
against the Human Oral Microbiome Database, we found another two pairs of ASVs which 
were exclusive between nodes but assigned to the same clones: Prev-b7f2 and Prev-71e7 
(Prevotella melaninogenica) and Stre-900d and Stre-0531 (Streptococcus parasanguinis). 
These results imply a possibility of niche specialization that is associated with disease status.  
 
 
Figure 5.4 Granulicatella adiacens variants set at the center of a network of closely related co-
occurring organisms. 
 
5.3 CHANGES IN NASOPHARYNGEAL MICROBIOME DURING 
RADIOTHERAPY 
We analyzed a total of 445 nasopharyngeal samples collected from 39 NPC patients in Paper 
III [239]. Among these, 27 (69.2%) patients achieved a complete response at the clinical check-
up three months after completion of radiotherapy and were classified as early responders; the 
remaining 12 patients completely responded within 24 months and were classified as late 
responders. 
We observed that the global structure of the nasopharyngeal microbiome among NPC patients 
changed over time in a constant manner, along with the treatment progress (Figure 5. 5, A and 
B). Volatility plots illustrated a consistent change in the first principle coordinate axis (PC1) 
along with sampling time; we also noticed that the changes in PC2 differed by patients ’
response to treatment. Results from the linear mixed-effects models (LMEs) estimating the 
change in weighted UniFrac distance support the volatility plots that the global nasopharyngeal 
microbiome changed significantly during treatment (slope, P-value = 0.0005; Figure 5.5 C). 
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Moreover, we found larger magnitude of the longitudinal changes among early responders than 
late responders, indicating significantly different trajectories between the two groups (P-value 
= 0.0005; Figure 5.5 D).  
 
Figure 5.5 Global change of nasopharyngeal microbiome over treatment course. 
 
We quantified the longitudinal differences in abundance of 73 abundant ASVs between the 
early and late responders (log-2 transformed). By applying smoothing-spline analysis of 
variance (SS-ANOVA), we identified 23 abundant ASVs with significant differences between 
groups (FDR < 0.05). Based on the similar pattern of changes, the estimated ratios between 
abundance in the early and late responders of 73 ASVs were clustered and visualized as a 
heatmap in Figure 5.6. In cluster C, half of the ASVs (gTherm.b26c, gTherm.087b, 
gTherm.94d, fCaulo.a200, gAcine.4f58, gRalst.edc7, gAcine.dfae, and gAcine.4c95) differed 
between groups since radiotherapy and consistently to the end. Most of these ASVs were 
assigned to genera Ralstonia and Thermus. Notably, some ASVs were assigned to the same 
genera, but showed different dynamic trajectories (increased, decreased, and relatively stable) 
across the treatment, such as members of the genus Acinetobacter (gAcine.32b4 and 
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gAcine.efe8 in Cluster A, compared to gAcine.4f58, gAcine.4c95, and gAcine.dfae in Cluster 
C), which might reflect niche specialization within the same genus. 
 












6.1 INTERPRETATION AND IMPLICATIONS 
6.1.1 Dietary patterns are associated with NPC risk 
Using food frequency data from the NPCGEE project in southern China, we identified similar 
dietary patterns in both adolescence and adulthood that were associated with NPC risk in 
endemic areas, in Paper I. We demonstrated a clear negative association between higher 
consumption of the “plant-based diet” and NPC risk, as well as a strong positive association 
with higher intake of the “animal-foods-based diet.” After mutual adjustment for adolescent 
and adulthood patterns, we observed that the OR estimates of adulthood patterns remained 
mostly unchanged, while associations with adolescent patterns were attenuated and no longer 
evident.  
These findings suggest that adult dietary patterns are better in predicting NPC risk in southern 
China. It could be explained partly by underlying cumulative effects of diets rich in plants or 
high in animal foods along time, while it could also be affected by recall bias (in that people 
tend to provide more accurate information for recent than for distant diet). The CUP Reports 
suggest foods from plant sources, such as grains, fresh non-starchy vegetables, and fruits, 
decrease risks of colorectal cancer and many aerodigestive cancers, with strong evidence [61]. 
Meanwhile, they report that foods from animal sources, such as processed meat and red meat, 
increase colorectal cancer risk with substantial evidence. We cannot eliminate the possibility 
that our observed associations capture the underlying effects of foods from plants and animals 
on cancer risk in general, rather than NPC-specific effects. Therefore, our findings not only 
provide evidence for the possibility of primary prevention of NPC through dietary intervention 
but also support the public health recommendations of “eat a diet rich in wholegrains, 
vegetables, fruits and beans” as well as “limit consumption of red and processed meat” [61]. 
Notably, we found a positive association between higher intake “preserved/salted diet” during 
adolescence in the joint analysis, although it did not meet the statistical significance. In line 
with previous evidence showing the earlier exposure to Cantonese-style salted fish, the higher 
NPC risk, our finding may support an earlier susceptible exposure window for a preserved-
foods diet concerning NPC risk. Although conducting a birth-cohort study on NPC would be 
difficult, if not impossible, our findings, together with numerous previous evidence, call for a 
further investigation focusing on early-life exposure and NPC risk. 
Besides, studies in Malaysian Chinese and Italy have reported that a diet rich in fresh vegetables 
and fruits was associated with a decreased NPC risk, and the Italian study suggested a positive 
association between an “animal unsaturated fatty acids” diet and NPC risk [236, 240]. 
Therefore, our findings may be partially generalized to other NPC endemic areas outside China 
(e.g., Southeast Asia) and non-endemic area (e.g., Italy). 
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6.1.2 Oral microbiome is associated with NPC risk 
We address the association between the oral microbiome and NPC risk, which may be 
explained partly by reduced microbial diversity and niche specialization among closely related 
organisms.   
Our results suggest that the oral microbiome is significantly associated with NPC status (i.e., 
case/control). These results are robust because they consider known confounders (e.g., 
residential community, smoking, and oral health) and less likely to be confounded by 
unmeasured factors because of the strong signal. It is also implausible that these results are 
related to cancer treatment since NPC patients were recruited after diagnosis but before taking 
radiotherapy/chemotherapy. However, we cannot rule out the effect of antibiotics (self-
medication) on the oral microbiome. Because the history of antibiotic use was unavailable 
(prior medical use was asked for both cases and controls, but the resulting information was not 
detailed enough to classify antibiotic use reliably), the current use of antibiotics was not an 
exclusion criterion. Although antibiotics could induce declined diversity, the oral microbiome 
has been suggested to be a more stable community than those at other body sites with regard 
to antibiotic treatment [241]. Besides, the significant drop in richness among NPC cases would 
require extensive use of antibiotics, which is not in line with interview data. 
Remarkably, our results reveal a significant association between NPC status and a pair of 
closely related ASVs, Gran-7770 and Gran-5a37, mapped to species Granulicatella adiacens. 
The presence/absence status and relative abundance of G. adiacens variants were significantly 
associated with disease status, and the variant carried by a participant predicted the community 
structure. These findings suggest that the G. adiacens variants might be a path through which 
NPC status shapes the oral microbiome. Furthermore, the co-occurring and co-excluding 
network centered on the G. adiacens variants may reflect partial niche specialization and link 
to metabolic changes. In the context of NPC in southern China, we hypothesize that G. 
adiacens and co-occurring organisms are involved in producing oncogenic metabolites (e.g., 
nitrate and nitrite production) and/or immune regulation [109, 242].  
However, given our cross-sectional study design, a disease status may either be a reaction to 
bacterial strain-specific variation or a factor driving this variation. It is also challenging, if not 
impossible, to evaluate how these organisms may function in concert without culture-based 
experiments. Besides, the limited resolution of operational taxonomic unit-based clustering in 
existing database challenges in-silico validation. Therefore, our findings call for future efforts 
to explore the temporality and the underlying mechanism. 
6.1.3 Changes in nasopharyngeal microbiome during radiotherapy are 
associated with NPC patients’ treatment outcome 
In Paper III, we demonstrated for the first time stable, temporal changes of the nasopharyngeal 
microbiome among NPC patients during radiotherapy-based treatment. We observed that the 
nasopharyngeal microbiome showed temporal shifts throughout treatment (i.e., UniFrac 
distance-based volatility plots); seven abundant ASVs (assigned as Corynebacterium) showed 
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a significant and consistent loss. This proof-of-principle data provides compelling evidence for 
exploring possible interactions between the host, radiotherapy, and commensal microbiome. 
Additionally, we reported a significant association between the microbial changes among NPC 
patients and their short-term outcomes. First, we found distinct and consistent separations in 
volatility plots regarding patients’ short-term outcomes (i.e., early responders vs. late 
responders). Results from LMEs modelling the magnitude of change (UniFrac distance-based) 
suggested a statistically significant difference between the early responders and late responders, 
which implied a possibility of feature-based differences. Thus, with the focus on 73 abundant 
ASVs, the non-parametric microbial interdependence test (NMIT)-based procedure showed 
that the microbial network's temporal changes over treatment among early responders differed 
from the changes among late responders. These findings challenge Anna Karenina’s principle, 
which would suggest that a favorable prognosis is associated with community stability [243]: 
in contrast, our results may implicate that a specific structure or trajectory of the 
nasopharyngeal microbiome reflecting less change during treatment indicates delayed response 
to radiotherapy. 
Furthermore, we identified 23 abundant ASVs significantly different between response groups 
during radiotherapy-based treatment. Five ASVs assigned to genera Ralstonia and Thermus 
showed a consistent difference between groups throughout treatment, from beginning to end; 
these organisms were at very low abundance or absent in early responders but present in late 
responders. Members of these extremophile genera are known to be radiation- or ROS-
resistant, suggesting a potentially plausible biological mechanism for their inclusion in these 
communities [244]. These findings may implicate bacterial resilience to radiotherapy as a 
feature of delayed response. We hypothesize that a community might be protective against both 
radiation-induced perturbations on the microbiome and radiation damage of the host cells. 
We acknowledge this as an exploratory observational study with a small number of NPC 
patients. However, it is a relatively large study in terms of the number of longitudinal samples 
collected and evaluated for each patient. Few studies have a larger sample size in the same 
research area due to the difficulty of repeated sampling in clinical practice. There is no 
comparable study that could be used as an external validation set for our findings. Although 
the short-term outcome was assessed at the first clinical check-up with 21 months of follow-
up, it might be insufficient in the context of direct applicability of the microbes as prognostic 
markers for NPC patients.  
We argue that several genera showed distinct and stable differences between response groups 
from treatment-naïve until the end of the full course of radiotherapy, which should be further 
validated for monitoring the initial treatment to improve the therapeutic outcome and moderate 
radiation-related toxicities. By focusing on NPC, for which radiotherapy is the most common 
treatment, we hypothesize that the relationship between the commensal microbiome and 
radiotherapy response may hold for other diseases and anatomical locations. Therefore, our 
findings call for more extensive longitudinal studies with long-term follow-up to verify the 
proposed hypotheses and serve as a base for generating new hypotheses in the coming future. 
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6.2 METHODOLOGICAL CONSIDERATIONS 
6.2.1 Observational studies 
Internal and external validities are crucial considerations during all stages of an observational 
study: internal validity captures to what degree a study has measured what it aimed to; external 
validity, also known as generalizability, describes how specific study results can be generalized 
to other settings [245]. Regarding internal validity, selection bias, information bias, and 
confounding are present to some extent in all observational studies, and need to be identified 
carefully and avoided or controlled as much as possible. We have attempted to address these 
biases and potential confounding in the presented papers, in line with the different study 
designs. The generalizability has been discussion in each paper previously. 
6.2.1.1 Case-control studies 
A case-control study is considered inexpensive, easy to conduct, and relatively quick compared 
to other study designs like cohort studies or randomized controlled trials, especially when 
investigating rare diseases or preliminary studies where little is known about the association 
between the exposure of interest and disease. Therefore, a population-based case-control design 
is suitable for the research questions in Study I and Study II.  
However, a case-control study is retrospective in nature: it starts with an outcome and traces 
back to the exposure, making it more sensitive to various biases and more challenging to 
establish the timeline of exposure-outcome association.  
Accordingly, great efforts have been made in the NPCGEE project to reduce selection bias and 
information bias, which are inevitable in case-control studies [222]. We equally applied the 
eligibility criteria of cases to controls, assuring that cases and controls came from the same 
study population. We also randomly selected controls from the total population registries in 
study area. We trained and monitored interviewers for the proper conduct of an interview in an 
identical manner for cases and controls (due to the lack of regional cancer registers in the study 
area, we identified NPC cases via a network of physicians who diagnosed and/or treated NPC 
at hospitals in the study area and informed the study interviewers afterward; thus the 
interviewers were not able to be blinded to subject’s disease status). Besides, we interviewed 
around 5% of controls by telephone after several unsuccessful attempts of a face-to-face 
interview in order to capture as many controls as possible. Furthermore, we used a structured 
electronic questionnaire to reduce logic errors and missing values and designed an illustrated 
booklet of various foods in different serving portions to facilitate participants in estimating 
dietary intake properly. Despite relatively high participation rates among cases (85.8%) and 
controls (82.7%), we acknowledge that a possible selection bias cannot be ruled out. 
To establish diet as a possible exposure for NPC development, we collected information on 
dietary intakes 10 years ahead of the interview for all participants, as well as 16-18 years of 
age for those above age 35. This, however, relies on remote memories of the participants and 
introduces a pervasive and inescapable recall bias. We excuse that recall bias for dietary intake 
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is likely non-differential between cases and controls, tending to obscure real differences. In 
Study II, we can only study the association between the oral microbiome and NPC status, 
without temporal ordering (cross-sectional case-control study). 
Confounding exists when a factor is associated with both exposure and outcome, but not an 
intermediator lying in the causal pathway between exposure and outcome. Complete 
elimination of unmeasured and unknown confounding is virtually impossible in an 
observational study. We used frequency matching on age, sex, and resident region in the 
NPCGEE project. Furthermore, we applied multivariate regression models to control for 
potential confounding based on prior knowledge and identified risk factors in the study 
population. Although socioeconomic status was not available directly, we argue that it 
correlates well with the occupation, housing type, and educational level, which were considered 
in the multivariate logistic regression models. We also examined whether age (born before or 
after 1963) modified the effect of dietary patterns as risk factors for NPC risk in Paper I.  
Before accepting the results and further interpreting them, one should be aware of a chance 
finding. P-values are not the arbiters of validity but a measure of chance, which advises us of 
the likelihood of a false-positive conclusion [245]. 
6.2.1.2 Cohort study 
There is no prior knowledge or evidence about how the nasopharyngeal microbiome changes 
during radiotherapy. We conducted a hospital-based prospective NPC patient cohort with the 
repeated collection of nasopharyngeal swabs along with radiotherapy-based treatment to 
provide longitudinal data. The repeated measurement design effectively controls for within-
individual variation, but limits the number of possible participants in this study. However, the 
longitudinal characteristic provides a comprehensive view of microbial diversity, an effective 
way for assessing the temporal microbial correlations, and an opportunity to reveal the degree 
of change of abundant features during the observation period [246]. 
In Paper III, all 39 NPC patients received the first clinical check-up at three months after 
completion of radiotherapy following the standard of care. Their short-term treatment 
outcomes were assessed and determined by the same three experienced oncologists based on 
RECIST criteria. Information bias is less likely to exist. Among 62 initially enrolled patients, 
23 were excluded due to various reasons [239]. We found no statistically significant difference 
in the distributions of age, sex, TNM stage, and treatment strategies between included patients 
and excluded patients. However, this study is limited by a lack of a comparative cohort as a 
validation set. 
6.2.2 Principal component analysis 
Dietary habits describe what foods people habitually choose to eat in their daily life. Unlike 
individual food items, habitual dietary intake is a multi-dimensional exposure covering 
numerous possible combinations of food items [89] and requires a comprehensive 
characterization. In observational studies, two strategies have been widely used for descriptive 
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purposes and to summarize dietary patterns for subsequent modelling and hypothesis testing: 
one is to describe a number of different food items using an established score, such as 
estimating adherence to the Mediterranean-diet score [247]; another is to efficiently summarize 
a large set of food items into a smaller group of variables (also known as dietary patterns) using 
a data reduction approach. As there was no eating score/index for the Chinese diet available 
when we planned Study I, we considered data reduction techniques. There are several 
commonly used approaches, including principal component analysis (PCA) and factor analysis 
(FA), reduced rank regression (RRR), and cluster analysis (CA) [248]. PCA and FA are two 
similar techniques chosen when a researcher is willing to summarize a broad set of food intakes 
as several dietary variables (i.e., components or factors) and to include these new variables in 
a regression model without prior theory/knowledge [249, 250]. In comparison, a RRR is a 
useful approach if a researcher has sufficient knowledge to determine response variables (such 
as body mass index, income level, etc.) as a set of intermediate factors associated with 
outcomes [251]. Unlike previous methods, groups/clusters generated from a CA are mutually 
exclusive, and there is no standard, well-validated procedure suitable across all settings [248]. 
Given the aims of (a) describing dietary habits in two study periods among participants from 
the NPCGEE project and (b) evaluating their associations with NPC risk, we decided to use 
PCA as the primary analysis, with an iterated principal FA as a sensitivity analysis. 
However, approaches like PCA/FA are not free from limitations: 
1) Researchers decide how many components/factors should be included in the downstream 
analysis, which is subjective. 
2) In many cases, only a low to a medium proportion of dietary habits variation is explained by 
selected components/factors.  
3) It can be challenging to interpret results, such as which food items/groups characterize the 
component/factor.  
4) Related to #3, naming the components/factors is also often subjective and challenging in 
practice. 
6.2.3 Biostatistical analyses in microbial studies 
Unlike traditional observational studies, there is no standard analytical workflow for human 
microbiome studies yet [228]. The choice of analytical strategies and statistical approaches 
differs due to the inherent characteristics of 16S rRNA amplicon sequencing data. For instance, 
the total number of bacteria in a biosample is not recoverable from the bacterial sequence 
counts due to numerous biases introduced by the DNA-PCR-sequencing procedures [252]. 
Therefore, relative instead of absolute abundances must be used, i.e., the data to be 
compositional: the relative abundances of all sequences in a sample are constrained to sum to 
one [228]. It means that when the relative abundance of a sequence increases, the relative 
abundances of the other sequences must decrease correspondingly, which is critical when 
interpreting results from a naïve analysis biologically. Additionally, a feature table representing 
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the number of times each feature (e.g., amplicon sequence variant [ASV], operational 
taxonomic unit [OTU]) is observed in each sample is sparse, often containing around 90% of 
zero counts; the data therefore generally does not follow a standard normal distribution even 
approximately, or more common discrete distribution like Poisson or negative binomial 
distribution. These characteristics lead to erroneous results and spurious correlations when 
naively applying traditional statistical procedures [252]. Consequently, many concepts and 
analytic approaches in microbial studies have been adopted from the field of ecology, and differ 
from methods commonly used in conventional epidemiological research [253].  
Here, we outline our experiences and considerations across the microbial methodological 
workflow in Paper II (Figure 6.1) and Paper III (Figure 6.2), starting from three key 
representations generated from amplicon sequencing data: 
1) The feature table is the fundamental data matrix of all the downstream analyses, containing 
the count (abundance) for all features (as rows) across all samples (as columns). In the 
literature, this feature table may be referred to as an ASV or OTU table, depending on the 
denoising technique employed.  
2) The taxonomy contains information on each feature's bacterial taxonomic classification in 
the context of the established hierarchy of known bacterial species.  
3) The phylogeny (phylogenetic tree) contains the evolutionary relationships between 
individual features reconstructed from the data at hand and acts as a backbone for many 
diversity analyses like, e.g., Faith’s phylogenetic diversity or UniFrac distance [254]. 
6.2.3.1 Oral microbiome 
With these three essential representations in place, we can address three scientific questions 
with regard to our NPC case-control Study II: 
1) How does the number of species/features in salivary samples differ by NPC status? 
2) How similar are NPC cases and controls in terms of microbiome composition? 
3) What features specifically are associated with differences between NPC cases and controls?  
The first and second questions can be answered by calculating alpha- and beta-diversity 
measures, central concepts in ecology, from our key data. Before calculating these diversity 
measures, however, normalization (standardizing the number of sequences across samples) 
must be performed to allow for valid comparison across samples, since the full range of species 
is rarely saturated, i.e., the higher the sequence yield for a sample, the higher the observed 
species count. A rarefaction curve is a useful guide for choosing a suitable normalization 
threshold to ensure that sufficient diversity can be observed in all samples [255]. However, 
rarefaction is a balance between maximizing the number of sequences per sample and keeping 
as many samples as possible. Thus, the choice of threshold is highly dependent on the studied 
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data. For the oral data, we chose a threshold of 6,500 sequences based on rarefaction curves 
(C-1 in Figure 6.1). 
Alpha-diversity as a concept quantifies within-sample diversity based on the observed number 
of species in a sample. Practically, many, often closely related measures for alpha-diversity 
have been proposed, of which we chose the Shannon index, which is based on relative species 
abundances, and Faith’s phylogenetic diversity, which takes into account phylogenetic 
relationships between species [256, 257]. Alpha-diversities were modelled as outcomes in 
multivariate ordinary least-squares regression to quantify the relationship between diversity 
and environment, adjusted for age, sex, and sequencing run number (C-2). Model fit for a range 
of different models, including different covariates, was assessed via the Akaike information 
criterion (AIC). The model with the lowest AIC score was selected as the best fitting. A “leave-
one-out” approach was used to estimate each covariate's relative contribution to the AIC metric. 
To visualize alpha-diversity in answering the first question, we used boxplots by NPC cases 
and controls.  
Beta-diversity conceptually captures pairwise dissimilarity in microbial composition between 
two samples, with the two most commonly employed measures being the Bray-Curtis 
dissimilarity and UniFrac distance. The Bray-Curtis dissimilarity quantifies the compositional 
dissimilarity between two samples based on species counts. The UniFrac distance calculates 
the distance between species present in two samples based on the underlying phylogenetic tree, 
as a fraction of non-shared branch lengths: weighted UniFrac is a quantitative measure 
considering the actual species counts, while unweighted UniFrac is only based on the presence 
or absence of species [258, 259]. Beta-diversity is typically presented as a sample-by-sample 
matrix. The distance or dissimilarity between two matrices can be approximated and visualized 
via principal coordinate analysis (PCoA). In a PCoA ordination, the n samples are placed in n-
dimensional space of synthetic variables (the principal coordinates, PCs) so  that the resulting 
Euclidean distances between the samples based on the principal coordinates approximate the 
original distance or dissimilarity matrix as well as possible. PCs are constructed in such a 
manner that the first PC (PC1) explains as much variation in distance between samples as 
possible, with subsequent PCs explaining less and less variation. Generally, the first two or 
three PCs are used for projection as 2-dimension plots or 3-dimension plots to visualize beta-
diversity.  
As the visualization of beta-diversities via PCoA in Study II showed differences between NPC 
cases and controls, we decided to continue with formal statistical inference. A combination of 
permutational multivariate analysis of variance (PERMANOVA/Adonis) and permutational 
analysis of multivariate dispersions (Permdisp) was used (C-3) [260]. PERMANOVA is a test 
for dissimilarity (here: beta-diversity) between groups, with the null hypothesis that the 
centroids and dispersions of the groups are all equal, while Permdisp tests for homogeneity of 
dispersions within each group, with the null hypothesis that there is no difference in dispersion 
across groups. In Study II, a permutation P-value < 0.001 from PERMANOVA based on 
UniFrac distances implies that NPC cases and controls have statistically significantly different 
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beta-diversity structures. However, this does not distinguish whether the difference is primarily 
due to variation in within-group dispersion, or primarily due to shifts in centroids between 
groups; a complementary Permdisp test with a non-significant P-value (> 0.55) indicates the 
latter case. 
The Adonis-implementation of PERMANOVA also reports an R2 measure of variance 
explained that describes how variation in community structure can be attributed to the main 
exposure (here: NPC status) or to other covariates included in the model. Base on this R2 
measure, we found that NPC disease status was the strongest factor associated with differences 
in microbial community structures when considering the presence/absence of species 
(unweighted UniFrac-based), and the second strongest (after smoking) element when also 
considering the relative abundances of species (weighted UniFrac-based). 
In the next step of the analysis, we addressed the question of differences in feature-based 
patterns between NPC cases and controls: specifically, but not limited to the question of which 
features are more prevalent in cases (controls) and which features are more abundant in cases 
(control)? Our approach is based on the same three key representations, but processing them in 
a different manner.  
To begin with, we filtered the feature table by defining presence as a relative abundance greater 
than 0.02% (corresponding to the shallowest sequencing depth for the abundant counts) in at 
least 10% of samples in order to eliminate noise and unreliable measurements and to avoid 
spurious correlations. This resulted in 245 abundant ASVs (C-4). In addition to age, sex, and 
sequencing run, we also chose to include covariates with an Adonis R2 at least 60% of the 
value associated with NPC (weighted or unweighted UniFrac) in the preceding global analysis 
for full adjustment in the feature-based analyses, to account for potential confounding; this led 
to the inclusion of smoking, residential community, and oral health. 
As NPC disease status was strongly associated with the microbial community structure 
considering the presence/absence of species, we first aimed to identify feature patterns (focused 
on the presence/absence of species) differed between NPC cases and controls. Thus, we fitted 
log-binomial regression models (approximated via a Poisson regression with robust standard 
errors) for presence/absence as a binary outcome for all 245 abundant ASVs, adjusting for age, 
sex, sequencing run, smoking, residential community, and oral health (C-5). A Benjamini-
Hochberg FDR corrected P-value of 0.05 was considered as statistically significant. At this 
significant level, we identified only two (out of 245) ASVs, namely Gran-7770 and Lact-eca9, 
which were more prevalent in cases, compared to 51 ASVs which were more prevalent among 
controls. This is in line with our previous findings that controls had higher alpha-diversity 
compared to cases.  
As we found strong associations between disease status and beta-diversity as measured by 
weighted UniFrac distance and Bray-Curtis dissimilarity, which incorporate relative 
abundances of species, we also wanted to study feature patterns of abundant ASVs based on 
relative abundances (C-6). We chose Phylofactor, a compositionally and phylogenetically 
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aware generalization of factor analysis to microbiome data, to evaluate how disease status 
corresponds to microbial abundance patterns (given the strong signal we saw in weighted 
UniFrac) [261]. Phylofactor is based on a specialized algorithm, “phylofactorization”, that aims 
to identify the most significant phylogenetic clades influencing variation in the data via their 
associations with different covariates. It uses isometric log transforms to model differences in 
the feature data with multivariate adjustment. Visualizations using phylofactorization can also 
map back to the phylogeny to provide taxonomic microbial annotation for each identified clade, 
which facilitates biological interpretation. The results from Phylofactor gave a summary of 
microbial abundance patterns associated with NPC status, sorted by explained variability. We 
found that the results highlight that individual ASVs like Gran-7770 and Gran-5a37, were 
significantly associated with NPC status, with Gran-7770 more abundant in cases and Gran-
5a37 more abundant in controls.  
As a complement to the Phylofactor, we also used a modified multivariate analysis of 
composition of microbiomes (ANCOM) with the abundant ASVs. ANCOM is also a 
compositionally aware statistical framework that compares log ratios of the abundance for each 
ASV to the abundance of all remaining ASVs one at a time; it controls the resulting risk of 
false discoveries in detecting differentially abundant ASVs with this approach while still 
maintaining high statistical power [262]. In the ANCOM model, we adjusted for age, sex, 
sequencing run, smoking, residential community, and oral health. Results from ANCOM 
corresponded well with Phylofactor and provided us microbial abundance patterns of 
individual features. 
After addressing our three original questions, we decided to investigate the surprising finding 
that two ASVs, Gran-7770 and Gran-5a37, repeatedly appeared in almost all feature-based 
analyses (C-7). First, we conducted a “background investigation” for these ASVs in the 
literature, microbiome databases, and our data. We found that these ASVs represent closely 
related organisms, or variants, of Granulicatella adiacens, and almost every participant in our 
study carried at least one variant. Second, a multinomial logistic regression was used to verify 
the associations between disease status and the variant carried by participants. The modelling 
results indicate that NPC cases were more likely to carry Gran-7770, while controls were more 
likely to carry Gran-5a37. We also tried to validate our findings using the publicly available 
data: however, as almost all the available oral microbiome data is at OTU-based resolution, 
which is not comparable with ASV-based data, with resolution down to single-nucleotides. We 
were, however, able to investigate the presence of other species that Granulicatella 
adiacens might interact within our material (C-8): we used the sparse co-occurrence network 
investigation for compositional data (SCNIC) to generate and analyze co-occurrence networks 
among the abundant ASVs [263]. Again, surprisingly and amazingly, we identified a co-
occurring and co-excluding network centered on the G. adiacens variants; this may reflect 
partial niche specialization and links to metabolic changes [264]. 
Nevertheless, given our cross-sectional design, a disease status may either equally be a driver 
or a consequence of bacterial strain-specific variation. Besides, it is difficult to evaluate further 
 
 41 
how these organisms may function in concert without culture-based experiments, and we 
decided to end the oral microbial adventure here. 
 
 
Figure 6.1 Methodological consideration about biostatistical analyses in Paper II. C-n: 
considerations during the workflow. 
 
6.2.3.2 Nasopharyngeal microbiome 
For investigating the nasopharyngeal microbiome during radiotherapy in Study III, we started 
our workflow with the same three essential representations generated from 16S-amplicon 
sequencing data: feature table, taxonomy, and phylogeny. However, given the different 
anatomical location and prospective cohort design with repeated sampling, the methodological 
considerations and research questions are inevitably different from those in Study II: 
1) How many and which species/ASVs can be observed in nasopharyngeal samples?  
2) How does the nasopharyngeal microbiome change along with radiotherapy-based treatment? 
3) How similar is the nasopharyngeal microbiome between the early and late responders? 
Based on rarefaction curves, we rarefied feature table to 1,500 sequences. Alpha- and beta-
diversities were computed afterward. To test for differences in alpha-diversity between 
sampling time points and response groups, we used the pairwise Kruskal-Wallis test; we found 
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no statistically significant evidence for such differences. This is reasonable because samples 
collected longitudinally from the same individual are more likely to be similar to each other, 
which means that they are not independent (C-2). 
Thus, we wanted to explore how the microbiome changes over sampling time, in parallel with 
treatment progress. We created a volatility visualization, which shows interactive line plots to 
represent how the nasopharyngeal microbiome changes across time in one or more groups (by 
response, by individual, etc.). Both alpha- and beta-diversities (represented by PCs) were 
visualized. We observed a clear shift in the nasopharyngeal microbiome as a whole in PC1, as 
well as a separation between early and late responders in PC2 over treatment, based on 
weighted UniFrac distances (i.e., reflecting abundance). However, we found no such patterns 
for unweighted UniFrac distance-based and Shannon index-based analyses. Together, these 
results suggest that the change of the nasopharyngeal microbiome and the different patterns 
between groups may be associated with the relative abundance of species in the community 
rather than their presence/absence (C-3).  
Consequently, we attempted to measure the magnitude of change in the microbiome in terms 
of weighted UniFrac distance across treatment by defining the variable Δ-wUF(t), 
corresponding to the length of the (t-1)-th step of a subject's trajectory through microbial space 
(C-4). By transforming the distance matrices of successive time points into values of the 
magnitude of change, we were able to fit a series of linear mixed-effects models (LMEs), 
allowing for varying degrees of change over treatment course as well as an examination of 
between-subject variation: based on the model comparison, we could assess whether there was 
significant change over treatment, whether the change differed by treatment outcome, and 
whether the change differed among individuals. Differences between nested models were 
tested via likelihood ratio tests. AIC was used to compare different models. To address 
sensitivity towards possible violations of model assumptions, standard LME inference was 
complemented with the parametric bootstrap P-values. Based on this modelling approach, we 
concluded that our data presented evidence for a). a stable, temporal change in the 
nasopharyngeal microbiome among NPC patients during radiotherapy-based treatment; b). 
different patterns of change between early and late responders.  
In order to examine patterns of change for individual features, we started as for Study II by 
filtering the feature table, in this case with a threshold of relative abundance greater than 0.1% 
(corresponding to the shallowest sequencing depth for the abundant counts) in at least 10% of 
samples, resulting in 73 abundant ASVs (C-5).  
As mentioned, samples collected from the same individual are not independent. Thus, we 
would like to explore the subject-specific time dynamics of the abundant features as a whole 
during treatment, and examine whether there is a difference between response groups (C-6). 
Therefore, we employed the non-parametric microbial interdependence test (NMIT) 
permutational testing framework [265]. Briefly, for each subject, a within-subject correlation 
matrix between the logarithmized relative abundances across sampling time points was 
calculated as a measure of subject-specific time dynamics; and the differences between subjects 
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were captured by the Frobenius norm (i.e., the sum of squared differences) of their relative 
within-subject correlation matrices, resulting in a subject-by-subject matrix of coefficients 
quantifying the dissimilarity of time dynamics between subjects. Differences between the 
groups were visualized using a PCoA approximation. Based on the results of the 
PERMANOVA (P-value  = 0.014) and Permdisp tests (P-value = 0.315), we suggest that the 
subject-specific time dynamics differed between the early and late responders. The difference 
is more likely due to between-group variation rather than a difference in within-group variation.  
Meanwhile, we also wanted to investigate whether individual features changed over treatment 
(C-7). We modelled the trajectory of observed counts for each ASVs via smoothing-spline 
ANOVA (SS-ANOVA) [266], which fits smoothing-spline curves to the longitudinal 
trajectories of log-2 transformed differences in abundance between two response groups, using 
a penalized least-squares approach. These predicted trajectories summarize how an ASV's 
relative abundance between early and late responders shifts over sampling time. The jackknife-
based penalty term in this model is explicitly designed as a regularization parameter to avoid 
overfitting the spline terms. For ensuring statistical robustness, we also increased the number 
of random re-samples to k = 10,000 to allow for multiple testing adjustment, and a FDR < 0.05 
was considered as statistically significant. We identified 23 out of 73 abundant ASVs that 
statistically significantly differed between early and late responders over time (FDR < 0.05).  
Among significant ASVs, 5 ASVs assigned to genera Ralstonia and Thermus showed a 
consistent difference between early and late responders from the beginning to the end of 
treatment; these organisms were at very low abundance or absent in early responders but 
present in late responders. These results may implicate bacterial resilience to radiotherapy as a 
feature of delayed response.  
However, given the relatively small sample size, observational design, and limited follow-up 
time in Study III, we were limited to further investigate whether the change is associated with 
patient’s long-term outcomes (e.g. 5-year overall survival rate, 5-year locoregional control rate, 
etc.) and verify our results in a validation cohort. Nonetheless, we believe that these findings 
are essential as a proof of principle and hope that our work will raise researchers’ interest in 
radiation-related changes in the human commensal microbiome and lead to more extensive 
longitudinal investigations. There are some plans for continuously studying this topic, which 




Figure 6.2 Methodological consideration about biostatistical analyses in Paper III [265-267]. 
C-n: considerations during the workflow. 
 
6.3 ETHICAL CONSIDERATIONS 
The data and saliva samples used in Study I and Study II were derived from the NPCGEE 
project, which was approved by the institutional ethical review board of Harvard T.H. Chan 
School of Public Health (Boston, United States), the Regional Ethical Review Board in 
Stockholm (Sweden), the Institute for Viral Disease Control and Prevention of the Chinese 
Center for Disease Control and Prevention (Beijing, China), Sun Yat-sen University Cancer 
Center (Guangzhou, China), and Guangxi Medical University (Nanning, China). During the 
interview, all participants were informed and provided consent of the future utility of 
questionnaire data and biosamples. The data and nasopharyngeal samples used in Study III 
were collected from the prospective NPC patients cohort in the First Affiliated Hospital of 
GXMU (Nanning, China), which was approved by the Ethical Review Committee of the First 
Affiliated Hospital. All participants were informed and provided consent of the future utility 
of questionnaire data and biosamples. 
The questionnaire data used in Study I and II is stored on the server at the Department of 
Medical Epidemiology and Biostatistics, Karolinska Institutet, Sweden. Data manager of the 
NPCGEE project replaced the identification number of questionnaire for each participant by 
an auto identification number of electronic questionnaire, which is used for linkages between 
sections of questionnaire data by sub-users. The sub-users cannot get access to the original 
questionnaire data. Saliva samples used in Study II are stored at Guangxi Medical University, 
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and the subsequent 16S-amlicon sequences have been made publicly available and stored at 
the European Nucleotide Archive [268]. The only metadata can be accessed is sex, disease 
status (case/control), and sequencing plate number. In Study III, the clinical data and 
nasopharyngeal samples are stored at Guangxi Medical University. The clinical data of NPC 
patients, including age, sex, cancer stage, treatment strategy, sampling time, and response 
status, as well as 16S-amplicon sequence is stored on the servers at Karolinska Institutet, which 
was approved by the Regional Ethical Review Board in Stockholm (Sweden). 
 Tingting Huang, and the corresponding authors of Study I - III are the guarantors of these 
works and, as such, have full access to all the data and samples, and take responsibility for the 
integrity of the data and the accuracy of the data analysis. 
Ethical approvals from Regional Ethical Review Board in Stockholm related to this thesis 
work include: Dnr 2009/1293-31/3 and Dnr 2015/175/39 (for Study I and II); Dnr 2017/1393-









 Plant-based and animal-foods-based diets are associated with nasopharyngeal 
carcinoma risk (in differential direction), which supports the possibility of primary 
prevention of nasopharyngeal carcinoma through dietary intervention. 
 
 Oral microbiome is associated with nasopharyngeal carcinoma risk. The niche 
specialization among closely related commensals associated with nasopharyngeal 
carcinoma status, calls for future culture-based investigations. 
 
 Stable, temporal changes of the nasopharyngeal microbiome among nasopharyngeal 
carcinoma patients during radiotherapy-based treatment are observed. These changes 
are associated with patients’ short-term clinical outcomes measured three months after 
the completion of radiotherapy. Our findings call for more extensive longitudinal 
studies with long-term follow-up for verification, and serve as a base of generating new 







8 FUTURE PERSPECTIVE 
As concluded, this thesis has demonstrated the associations of dietary habits and suggested a 
potential diet intervention, addressed that subspecies niche specialization of oral microbiome 
is associated with NPC risk, and provided proof-of-concept evidence on the possibility of 
nasopharyngeal microbiome contributing to NPC treatment. Meanwhile, our findings trigger 
new thoughts and hypotheses, which call for future efforts. 
8.1 DIET AND NPC 
The take-home messages from Paper I are: 
1) Having more wholegrains, vegetables, fruits, and beans, and limiting the intakes of red meat 
and processed meat in daily diet shall be widely recommended not only because it may reduce 
the risk of NPC, and more importantly, it may improve the overall health and prevent many 
chronic diseases not limited to cancers. 
2) Although a birth-cohort study in an endemic area is necessary and sufficient for studying 
NPC etiology given that early-life exposure is deemed to be essential, unluckily, it is almost 
impossible in reality. However, well-designed case-control studies and cohort studies with high 
quality are warranted in further understanding the disease, supplemented by individual 
participant data meta-analysis. 
8.2 ORAL MICROBIOME AND NPC 
Based on the same study setting of Paper II, we shall further investigate whether oral 
microbiome is associated with EBV infection. For example, whether oral microbiome is 
associated with EBV load/EBV strains among the study participants, what are the correlation 
patterns among NPC cases and controls, whether oral microbiome is associated with NPC 
cases’ clinical characteristics (e.g., cancer stage, treatment outcome, and survival)? 
On the other hand, we hypothesize that G. adiacens and co-occurring microorganisms are 
involved in the generation of oncogenic metabolites (e.g., nitrate and nitrite production) and/or 
immune regulation. Culture-based experiments are required. Furthermore, the established 
immortalized nasopharyngeal epithelial cells with type II EBV latency may be an ideal working 
model. This will request a multidisciplinary, international approach, involving experts from 
microbiology, virology, biochemistry, and cancer biology. 
8.3 COMMENSAL MICROBIOME DURING RADIOTHERAPY 
In Paper III, we provide compelling data on the possibility that commensal 
microbiome/microbes might be biomarkers for treatment outcome prediction and monitoring. 
Next step, we plan to validate the results and evaluate the performance of commensal 
microbiome as a biomarker in a larger NPC-patient-cohort (with less sampling time points) 
using different detection measures (16S-based sequencing, quantitative PCR, etc.). We will 
also look for more collaboration with other cancer centers. 
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8.4 NP-MICROBIOME AMONG HIGH-RISK POPULATION OF NPC 
We are conducting a study on evaluating the association between the nasopharyngeal 
microbiome (nasopharyngeal swabs) and EBV status (serum EBV titers, EBV load in the 
nasopharynx, etc.) based on an NPC cohort in southern China with around 900 participants 
who were tested EBV positive (serum titers) at the baseline survey.  
8.5 COMMENSAL MICROBIOME AND OTHER CANCERS 
Besides NPC, we found a significant difference in the vaginal microbial community between 
patients with cervical cancer and healthy controls. We identified several microorganisms with 
increased relative abundance along with radiotherapy among patients treated with pelvic 
IMRT-based treatment (unpublished data). We will investigate the potential association 
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